Track PSTV and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Plus Therapeutics Inc
6420 LEVIT GREEN BOULEVARD, Houston, TX, United States, 77021
IPO
2000
Employees
28
Industry
Biotechnology
Sector
Healthcare
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20250+1
1
Q3 20250+1
1
2-quarter cumulative
0 sells2 buys
Analyst Ratings
3 analysts covering
Buy67%recommend buy
Buy
2
Hold
1
Sell
0